First Patient Enrolled in DISRUPT CAD IV Clinical Study for Treatment of Severely Calcified Coronary Arteries SANTA CLARA, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the company […]
Coronary/Structural Heart
Acasti Pharma Announces Publication of CaPre Pharmacokinetics Study in a Leading Peer-Reviewed Journal
Reinforces prior study results demonstrating proportional dose response and that bioavailability of CaPre is not meaningfully affected by the fat content of a meal LAVAL, Québec, Nov. 07, 2019 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, […]
Recardio’s Digital Platform, CardioCare, Rolled Out in Europe
SAN FRANCISCO, Nov. 6, 2019 /PRNewswire/ — Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that it has rolled out its digital platform, CardioCare, throughout Europe to support its future clinical development programs in cardiovascular. Recardio’s Digital Platform CardioCare was awarded and presented at the ESC Conference 2018 and is now […]
Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN‑4001, First Multigenic Investigational Therapeutic Candidate for Treatment of Heart Failure
– Company to Present Preliminary Data at American Heart Association Scientific Sessions – GERMANTOWN, Md., Nov. 7, 2019 /PRNewswire/ — Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), today announced the completion of enrollment and dosing in its Phase 1 trial of INXN-4001, a […]
Saranas Announces First Commercial Case With Early Bird® Bleed Monitoring System in the U.S.
Novel technology offers physicians first and only real-time detection and monitoring of endovascular bleed complications HOUSTON–(BUSINESS WIRE)–Saranas, Inc. today announced completion of the first U.S. commercial case using the Early Bird® Bleed Monitoring System for real-time detection and monitoring of endovascular bleed complications. Dr. Robert Kipperman, co-director of the Structural Heart […]
Edwards SAPIEN 3 TAVI Receives Expanded Approval In Europe
Superior TAVI Valve Indicated for All Patients Diagnosed with Aortic Stenosis IRVINE, Calif., Nov. 6, 2019 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received CE Mark to expand use of the Edwards SAPIEN 3 […]
Neovasc to Submit Full PMA Application for Neovasc Reducer™ in 2019
VANCOUVER, Nov. 01, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it intends to submit […]
First U.S. Patients Treated with Impella 5.5 with SmartAssist, a Minimally Invasive, Forward Flow Heart Pump
DANVERS, Mass.–(BUSINESS WIRE)–Three cardiac surgeons at Cleveland Clinic, Hackensack Meridian Health and Cedars-Sinai Medical Center are the first in the United States to implant Abiomed’s (NASDAQ: ABMD) newest heart pump, the Impella 5.5 with SmartAssist. Ed Soltesz, MD, Mark Anderson, MD, and Danny Ramzy, MD, have each successfully implanted multiple pumps during cardiac procedures at their hospitals. Mark […]
myTAIHEART Test Provides Evidence for Injury from Biopsy of Heart Transplant Recipients
MILWAUKEE, Wis.–(BUSINESS WIRE)–TAI Diagnostics, Inc., focused on developing innovative diagnostic tests for monitoring the health of transplanted organs, today announced the publication, “Effect of endomyocardial biopsy on levels of donor-specific cell-free DNA” in the October, 2019 issue of The Journal of Heart and Lung Transplantation. The clinical study presented in the paper was conducted jointly […]
Orsiro Coronary Drug-Eluting Stent Receives Market Approval in China
BIOTRONIK’s Ultrathin-Strut Drug-Eluting Stent Soon Available in China Following Market Approval BEIJING, China and BUELACH, Switzerland, October 30, 2019 – BIOTRONIK announced today that its Orsiro® coronary drug-eluting stent (DES) has been approved for sale in China by the National Medical Products Administration. The company expects to make the device available to Chinese patients […]



